Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Department of Ophthalmology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, South Korea.
Acta Ophthalmol. 2022 Dec;100(8):e1579-e1588. doi: 10.1111/aos.15149. Epub 2022 Apr 1.
To investigate long-term visual outcomes of patients with polypoidal choroidal vasculopathy (PCV) and typical neovascular age-related macular degeneration (nAMD) in the real-world setting.
Retrospective, multicenter, noninterventional consecutive cohort study. Two hundred eighty-five eyes of 261 patients with PCV and 902 eyes of 877 patients with typical nAMD, who could be followed up 1 year or longer from 2005 to 2018, were included. Mean changes in best-corrected visual acuity (BCVA) from baseline in the PCV and the typical nAMD groups were compared.
Mean follow-up period of total patients was 4.3 ± 2.8 (1-10) years. Baseline BCVA was better in the PCV group than that in the typical nAMD group (0.59 ± 0.52 versus 0.79 ± 0.63 logMAR, p < 0.001). The mean changes in BCVA from baseline in the PCV and nAMD group were +2.1 and -0.1 letters at 1 year, -0.2 and -3.7 letters at 3 years, -3.9 and -10.5 letters at 5 years and - 8.7 and - 12.1 letters at 7 years, respectively. Before 2006, the initial BCVA was sustained for approximately 1 year in eyes with PCV and for less than half year in eyes with typical nAMD. However, after 2007, when anti-VEGF agents were available, the initial BCVA was sustained for 4 years in eyes with PCV, while it was sustained for 1 year in eyes with typical nAMD.
In the real-world, long-term BCVA deteriorated in both PCV and typical nAMD groups, but the PCV group showed better visual outcomes than the typical nAMD group.
在真实环境中研究息肉样脉络膜血管病变（PCV）和典型新生血管性年龄相关性黄斑变性（nAMD）患者的长期视力结果。
回顾性、多中心、非干预性连续队列研究。纳入 2005 年至 2018 年期间可随访 1 年或更长时间的 261 例 285 只眼 PCV 患者和 877 例 902 只眼典型 nAMD 患者。比较 PCV 组和典型 nAMD 组从基线开始最佳矫正视力（BCVA）的平均变化。
所有患者的平均随访时间为 4.3±2.8（1-10）年。PCV 组的基线 BCVA 优于典型 nAMD 组（0.59±0.52 与 0.79±0.63 logMAR，p<0.001）。PCV 组和 nAMD 组从基线开始的 BCVA 平均变化分别为：1 年时增加 2.1 个字母，减少 0.1 个字母；3 年时减少 0.2 个字母，减少 3.7 个字母；5 年时减少 3.9 个字母，减少 10.5 个字母；7 年时减少 8.7 个字母，减少 12.1 个字母。在 2006 年之前，PCV 组的初始 BCVA 大约持续 1 年，而典型 nAMD 组的初始 BCVA 持续不到半年。然而，在 2007 年抗血管内皮生长因子药物问世后，PCV 组的初始 BCVA 持续了 4 年，而典型 nAMD 组的初始 BCVA 持续了 1 年。
在真实环境中，PCV 和典型 nAMD 两组的长期 BCVA 均恶化，但 PCV 组的视力结果优于典型 nAMD 组。
